This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neoplasms of Head & Neck  • Radiology of Head & Neck  • Radiation Therapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Mahmut Ozsahin, MD, PhD; Michael Betz, MD; Oscar Matzinger, MD; Luc Bron, MD; François Luthi, MD; Philippe Pasche, MD; David Azria, MD; René O. Mirimanoff, MD; Abderrahim Zouhair, MD

Arch Otolaryngol Head Neck Surg. 2006;132:141-145.

Objective  To assess the feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated radiotherapy (RT).

Design  Retrospective study.

Setting  University of Lausanne, Lausanne, Switzerland.

Patients  Thirty-three consecutive patients (male-female ratio, 4.5; median age, 54 years [age range, 39-76 years]).

Interventions  Between November 2000 and January 2003, the 33 patients were treated with curative definitive (n = 19) or postoperative (n = 14) RT with (n = 26) or without (n = 7) chemotherapy. All patients received conformal RT. Fractionation schedule consisted of concomitant-boost (Friday afternoon session) accelerated RT using 70 Gy (2 Gy per fraction) in 6 weeks in patients treated with definitive RT and 66 Gy (2 Gy per fraction) in 5 weeks and 3 days in the postoperative setting. Parotid glands received at least 50 Gy in all patients. Amifostine was administered to a total dose of 500 mg subcutaneously, 15 to 30 minutes before morning RT sessions.

Results  All patients received their planned treatment (including chemotherapy). Ten patients received the full schedule of amifostine (at least 25 injections), 9 received 20 to 24 doses, 4 received 10 to 19 doses, 5 received 5 to 9 doses, and 5 received fewer than 5 doses. Fifteen patients (45%) did not show any intolerance related to amifostine use. Amifostine therapy was discontinued because of nausea in 11 patients (33%) and hypotension in 6 patients (18%), and 1 patient refused treatment. No grade 3, amifostine-related, cutaneous toxic effects were observed. Radiotherapy-induced grade 3 acute toxic effects included mucositis in 14 patients (42%), erythema in 14 patients (42%), and dysphagia in 13 patients (39%). Late toxic effects included grade 2 or more xerostomia in 17 patients (51%) and fibrosis in 3 patients (9%). Grade 2 or more xerostomia was observed in 8 (42%) of 19 patients receiving 20 injections or more vs 9 (64%) of 14 patients receiving fewer than 20 injections (P = .15).

Conclusions  Subcutaneous amifostine administration in combination with accelerated concomitant-boost RT with or without chemotherapy is feasible. The major adverse effect of subcutaneous administration was nausea despite prophylactic antiemetic medication, and hypotension was observed in only 6 patients (18%).

Author Affiliations: Departments of Radiation Oncology (Drs Ozsahin, Betz, Matzinger, Azria, Mirimanoff, and Zouhair), Otorhinolaryngology (Drs Bron and Pasche), and Medical Oncology (Dr Luthi), Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Established and emerging uses of cytoprotection in head and neck cancer.
Rosenthal
Arch Otolaryngol Head Neck Surg 2006;132:129-130.
FULL TEXT